Pulse Biosciences Files 8-K

TL;DR

Pulse Biosciences filed an 8-K on 6/28. Check for updates.

AI Summary

Pulse Biosciences, Inc. filed an 8-K on June 28, 2024, to report other events and financial statements. The filing does not contain specific financial figures or details about the 'other events' beyond its classification.

Why It Matters

This 8-K filing indicates Pulse Biosciences is reporting significant events or financial updates, requiring investor attention for details on business developments.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for 'Other Events' and financial statements without immediate disclosed financial impact or significant operational changes.

Key Players & Entities

• Pulse Biosciences, Inc. (company) — Registrant
• June 28, 2024 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• 001-37744 (identifier) — Commission File Number
• 46-5696597 (identifier) — IRS Employer Identification No.
• 3957 Point Eden Way (address) — Principal Executive Offices
• Hayward (location) — City of Principal Executive Offices
• California (location) — State of Principal Executive Offices
• 94545 (zip_code) — Zip Code of Principal Executive Offices
• 510-906-4600 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock , par value $0.001 per share PLSE The Nasdaq Stock Mar
• $10 — mately six million units, at a price of $10 per unit, with each unit consisting of
• $11.00 — ur common stock at an exercise price of $11.00 per whole share ( provided , that, the
• $60 million — ate gross proceeds from the offering of $60 million. In the offering, Mr. Duggan, the Compa

Filing Documents

• plse20240627_8k.htm (8-K) — 29KB
• ex_693493.htm (EX-99.1) — 14KB
• 0001437749-24-021615.txt ( ) — 177KB
• plse-20240628.xsd (EX-101.SCH) — 3KB
• plse-20240628_def.xml (EX-101.DEF) — 11KB
• plse-20240628_lab.xml (EX-101.LAB) — 15KB
• plse-20240628_pre.xml (EX-101.PRE) — 11KB
• plse20240627_8k_htm.xml (XML) — 3KB

01

ITEM 8.01 Other Events. On June 28, 2024, Pulse Biosciences, Inc. (the "Company") issued a press release announcing the preliminary results of its previously announced rights offering. As of June 26, 2024, the final Expiration Date of the offering, eligible stockholders had subscribed to purchase approximately six million units, at a price of $10 per unit, with each unit consisting of one share of Company common stock and two warrants, each being a warrant to purchase one-half of one share of our common stock at an exercise price of $11.00 per whole share ( provided , that, the aggregate number of shares of our common stock that shall be issuable upon the exercise of each set of warrants included in a given subscription for Units shall be rounded up to the nearest whole share). The Company expects to receive aggregate gross proceeds from the offering of $60 million. In the offering, Mr. Duggan, the Company's Executive Chairman and majority stockholder, exercised rights to acquire approximately five million units. Once final subscriptions have been tabulated and confirmed by DTC, the Company expects to issue approximately six million shares in aggregate to all participating stockholders in the offering (but excluding up to six million shares of common stock underlying the warrants issued in the rights offering). The shares to be issued include approximately five million shares in aggregate to Mr. Duggan and affiliates of his, which will bring Mr. Duggan's current beneficial ownership in the Company to approximately 72%.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release issued by Pulse Biosciences, Inc. dated June 28, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PULSE BIOSCIENCES, INC. Date: June 28, 2024 By: /s/ Burke T. Barrett Burke T. Barrett President and Chief Executive Officer (Principal Executive and Principal Financial Officer)

View Full Filing

View this 8-K filing on SEC EDGAR